Updates are available Correction dated 2023-10-16
Click to view Correction: https://doi.org/10.1038/s41591-023-02639-3
-
Authors
Mummery, Catherine J. http://orcid.org/0000-0002-6739-0803
Börjesson-Hanson, Anne
Blackburn, Daniel J.
Vijverberg, Everard G. B.
De Deyn, Peter Paul
Ducharme, Simon http://orcid.org/0000-0002-7309-1113
Jonsson, Michael
Schneider, Anja
Rinne, Juha O. http://orcid.org/0000-0001-6369-0764
Ludolph, Albert C.
Bodenschatz, Ralf
Kordasiewicz, Holly
Swayze, Eric E. http://orcid.org/0000-0001-6430-6576
Fitzsimmons, Bethany
Mignon, Laurence
Moore, Katrina M.
Yun, Chris
Baumann, Tiffany
Li, Dan
Norris, Daniel A. http://orcid.org/0000-0003-2074-5862
Crean, Rebecca
Graham, Danielle L.
Huang, Ellen
Ratti, Elena
Bennett, C. Frank
Junge, Candice
Lane, Roger M.
-
Funding
Funding for this research was provided by:
Biogen
Ionis Pharmaceuticals
- License Information
-
More Information
Article History
Received: 1 September 2022
Accepted: 29 March 2023
First Online: 24 April 2023
Change Date: 16 October 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-023-02639-3
Competing interests
: C.J.M. reports advisory board membership for Roche, Lilly, Biogen and Ionis; research grants from Biogen; seminar chair for Biogen; chair of data safety monitoring board for AD trial led by Imperial College; supported by the NIHR Biomedical Research Centre dementia subtheme at UCLH. M.J. reports advisory board membership for Biogen Sweden AB and BioArctic AB. S.D. reports salary support from the Fonds de recherche du Québec – Santé; consultancies from Biogen, Wave Life Sciences, AZTherapies and Janssen Pharmaceuticals; advisory board membership and/or speaker fees from Eisai, Biogen, Sunovion, Innodem Neurosciences, HealthTech Connex and QurAlis; cofounder of AFX Medical Inc. E.G.B.V. reports consultancies from New Amsterdam Pharma, Treeway, ReMynd, Vivoryon, Biogen, Vigil Neuroscience, ImmunoBrain Checkpoint and Brainstorm Therapeutics. PI of studies with AC immune, CogRX therapeutics, New Amsterdam Pharma, Janssen, UCB, Roche, GreenValley, Vivoryon, ImmunoBrain, Alector and Alzheon and sub-I from DIAN-TU, Alzheon, Eli Lilly, Cortexyme, Biogen en Fuij Film Toyama. L.M., K.M.M., C.Y., D.L., D.A.N., R.C., C.F.B., C.J. and R.M.L. are employees of, and hold stock in, Ionis. D.L.G., E.H. and E.R. are employees of, and hold stock in, Biogen. The remaining authors declare no competing interests.
